Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Tau Tangles in Parkinson's Disease : A 2-Year Follow-Up Flortaucipir PET Study. / Hansen, Allan K; Parbo, Peter; Ismail, Rola; Østergaard, Karen; Brooks, David J; Borghammer, Per.

I: Journal of Parkinson's Disease, Bind 10, Nr. 1, 2020, s. 161-171.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{cd32ebceb27b48ae8adacdba70cfa498,
title = "Tau Tangles in Parkinson's Disease: A 2-Year Follow-Up Flortaucipir PET Study",
abstract = "BACKGROUND: Flortaucipir PET, a marker of tau tangles, has shown lower than expected cortical uptake in Parkinson's disease (PD), than would be predicted from neuropathologic estimates of Alzheimer's disease co-pathology. Instead, the most characteristic finding of flortaucipir imaging in PD is decreased uptake in the substantia nigra, reflecting reduction in its {"}off-target{"} binding to neuromelanin. We have previously reported these observations in cross-sectional studies.OBJECTIVE: Here, we present two-year follow-up data of cortical and nigral flortaucipir uptake in PD patients.METHODS: Seventeen PD patients received repeat flortaucipir PET two years after baseline. We interrogated vertex-based group-wise cortical tracer binding (SUVRs) with a cerebellar reference using the general linear model while mean substantia nigra SUVRs were compared with volumes of interest group comparisons and voxel-wise group analyses using ANOVA. Finally, we performed linear regressions of tau load with changes in MoCA and UPDRS motor scores.RESULTS: We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms. Signal reduction in the medial substantia nigra trended towards an association with worsening of motor symptoms.CONCLUSION: No significant increase in tau tangles occurred after a two-year follow-up of Parkinson's disease patients using flortaucipir PET.",
keywords = "Parkinson's disease, dementia, neurofibrillary tangles, melanins, positron emission tomography, POSITRON-EMISSION-TOMOGRAPHY, MONOAMINE-OXIDASE-B, BRAIN MAO-B, SUBSTANTIA-NIGRA, ALZHEIMERS-DISEASE, CHOROID-PLEXUS, NEUROMELANIN, BINDING, TRACER, ACCUMULATION",
author = "Hansen, {Allan K} and Peter Parbo and Rola Ismail and Karen {\O}stergaard and Brooks, {David J} and Per Borghammer",
year = "2020",
doi = "10.3233/JPD-191774",
language = "English",
volume = "10",
pages = "161--171",
journal = "Journal of Parkinson's Disease",
issn = "1877-7171",
publisher = "I O S Press",
number = "1",

}

RIS

TY - JOUR

T1 - Tau Tangles in Parkinson's Disease

T2 - A 2-Year Follow-Up Flortaucipir PET Study

AU - Hansen, Allan K

AU - Parbo, Peter

AU - Ismail, Rola

AU - Østergaard, Karen

AU - Brooks, David J

AU - Borghammer, Per

PY - 2020

Y1 - 2020

N2 - BACKGROUND: Flortaucipir PET, a marker of tau tangles, has shown lower than expected cortical uptake in Parkinson's disease (PD), than would be predicted from neuropathologic estimates of Alzheimer's disease co-pathology. Instead, the most characteristic finding of flortaucipir imaging in PD is decreased uptake in the substantia nigra, reflecting reduction in its "off-target" binding to neuromelanin. We have previously reported these observations in cross-sectional studies.OBJECTIVE: Here, we present two-year follow-up data of cortical and nigral flortaucipir uptake in PD patients.METHODS: Seventeen PD patients received repeat flortaucipir PET two years after baseline. We interrogated vertex-based group-wise cortical tracer binding (SUVRs) with a cerebellar reference using the general linear model while mean substantia nigra SUVRs were compared with volumes of interest group comparisons and voxel-wise group analyses using ANOVA. Finally, we performed linear regressions of tau load with changes in MoCA and UPDRS motor scores.RESULTS: We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms. Signal reduction in the medial substantia nigra trended towards an association with worsening of motor symptoms.CONCLUSION: No significant increase in tau tangles occurred after a two-year follow-up of Parkinson's disease patients using flortaucipir PET.

AB - BACKGROUND: Flortaucipir PET, a marker of tau tangles, has shown lower than expected cortical uptake in Parkinson's disease (PD), than would be predicted from neuropathologic estimates of Alzheimer's disease co-pathology. Instead, the most characteristic finding of flortaucipir imaging in PD is decreased uptake in the substantia nigra, reflecting reduction in its "off-target" binding to neuromelanin. We have previously reported these observations in cross-sectional studies.OBJECTIVE: Here, we present two-year follow-up data of cortical and nigral flortaucipir uptake in PD patients.METHODS: Seventeen PD patients received repeat flortaucipir PET two years after baseline. We interrogated vertex-based group-wise cortical tracer binding (SUVRs) with a cerebellar reference using the general linear model while mean substantia nigra SUVRs were compared with volumes of interest group comparisons and voxel-wise group analyses using ANOVA. Finally, we performed linear regressions of tau load with changes in MoCA and UPDRS motor scores.RESULTS: We found no significant changes in substantia nigra or cortex flortaucipir uptake in Parkinson's disease patients over two years and no association with changes in cognitive symptoms. Signal reduction in the medial substantia nigra trended towards an association with worsening of motor symptoms.CONCLUSION: No significant increase in tau tangles occurred after a two-year follow-up of Parkinson's disease patients using flortaucipir PET.

KW - Parkinson's disease

KW - dementia

KW - neurofibrillary tangles

KW - melanins

KW - positron emission tomography

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - MONOAMINE-OXIDASE-B

KW - BRAIN MAO-B

KW - SUBSTANTIA-NIGRA

KW - ALZHEIMERS-DISEASE

KW - CHOROID-PLEXUS

KW - NEUROMELANIN

KW - BINDING

KW - TRACER

KW - ACCUMULATION

U2 - 10.3233/JPD-191774

DO - 10.3233/JPD-191774

M3 - Journal article

C2 - 31815700

VL - 10

SP - 161

EP - 171

JO - Journal of Parkinson's Disease

JF - Journal of Parkinson's Disease

SN - 1877-7171

IS - 1

ER -